Orchestra BioMed Holdings, Inc.
OBIO
$2.78
$0.207.75%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.64M | 2.65M | 2.08M | 2.22M | 2.76M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.64M | 2.65M | 2.08M | 2.22M | 2.76M |
| Cost of Revenue | 204.00K | 193.00K | 166.00K | 176.00K | 186.00K |
| Gross Profit | 2.43M | 2.45M | 1.91M | 2.04M | 2.57M |
| SG&A Expenses | 23.93M | 22.22M | 22.89M | 21.74M | 20.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 66.94M | 62.75M | 60.37M | 56.60M | 54.27M |
| Operating Income | -64.30M | -60.11M | -58.29M | -54.38M | -51.51M |
| Income Before Tax | -61.02M | -57.69M | -55.58M | -51.64M | -49.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -61.02 | -57.69 | -55.58 | -51.64 | -49.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.02M | -57.69M | -55.58M | -51.64M | -49.12M |
| EBIT | -64.30M | -60.11M | -58.29M | -54.38M | -51.51M |
| EBITDA | -63.99M | -59.81M | -58.00M | -54.09M | -51.22M |
| EPS Basic | -1.66 | -1.60 | -1.57 | -1.47 | -1.49 |
| Normalized Basic EPS | -1.03 | -0.97 | -0.96 | -0.89 | -0.91 |
| EPS Diluted | -1.66 | -1.60 | -1.57 | -1.47 | -1.49 |
| Normalized Diluted EPS | -1.03 | -0.97 | -0.96 | -0.89 | -0.91 |
| Average Basic Shares Outstanding | 147.26M | 144.34M | 141.96M | 140.78M | 132.64M |
| Average Diluted Shares Outstanding | 147.26M | 144.34M | 141.96M | 140.78M | 132.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |